We describe multiple alternative transcripts of uroporphynnogen decarboxylase mRNA in normal individuals and patients with familial porphyria cutanea tarda. mRNA was reverse-transcribed, subjected to the polymerase chain reaction, and analyzed for nucleotide sequence. Seven different transcripts were characterized, and a cryptic splice acceptor site was identified in intron 1. In all mRNAs the exons abutted at previously defined exon boundaries. Characterization of the splice junctions in the genomic DNA showed that splice donor and acceptor sequences complied with the consensus sequences for these sites except for the splice acceptor sequences of exons 3 and 10. These deviations were present in two normal individuals and one patient with familial porphyria cutanea tarda and were thus unable to explain the multiple aberrant uroporphyrinogen decarboxylase transcripts. We conclude that apparent deletions observed in transcripts derived from the uroporphyrinogendecarboxylase gene in patients with familial porphyria cutanea tarda should be interpreted with caution. 
hepatoerythropoietic porphyria the UROD activity is
<10% (11).
Several studies have examined the molecular basis for fPCT. A point mutation has been described in the UROD gene eDNA in one family with IPCT. In this family, a G-.C substitution (GGG-'GCG) at position 860 of the cDNA resulted in valine replacing glycine at amino acid position 281 and resulted in a catalytically active but unstable protein (7). More recently, Garey et al. (12) described a deletion of exon 6 from the mRNA, which was attributed to a G-*C substitution at the 5' end of intron 6. This defect was observed in 5 of 22 unrelated families with IPCT. However, in a number of other families, no defect in the UROD gene cDNA was defined.
In this study, we examined two normal individuals, an index patient with fPCT, and one of the index patient's offspring, also diagnosed with IPCT. We observed multiple UROD transcripts in all four subjects and, in all of them except the proband's daughter, we characterized the intron/exon boundaries of their UROD mRNA.
MaterIals and Methods Subjects
The two normal individuals, #1 and #2, were healthy laboratory workers without any clinical or biochemical evidence of porphyria cutanea tarda (PCT). The index patient and her daughter were diagnosed with fPCT on the basis of skin photosensitivity typically associated with PCT and confirmatory porphyrin biochemistry.
Concentrations
of porphyrins in their urine, feces, and plasma were increased, and isocoproporphyrin, a diagnostic marker of PCT (13), was detected in their feces. Erythrocyte UROD activity was decreased in the proband as well as in three other family members with clinical PCT, including the aforementioned daughter. The procedure for handling the subjects used in this study was in accordance with the guidelines of the Royal Melbourne Hospital ethics committee.
Procedures

Eiythrocyte
[TROD activity measurement.
UROD activity was measured in the erythrocytes of both normal individuals and patients with fPCT. A sample of whole blood was incubated with pentacarboxylic acid porphyrinogen 1 (oxidized form; Porphyrin Products, Logan, UT) at 37#{176}C for 30 mm at pH 6. The reaction was terminated by the addition of an equivolume mixture of 0.61 mmol/L trichioroacetic acid and dimethyl sulfoxide containing mesoporphyrin (Porphyrin  Products) as an internal standard.
The coproporphyrin produced was can incorporate 10 nmol of dNTPs in 30 mm at 74#{176}C and therefore extend at a rate of 1000 bases/min (18). gDNA was amplified by PCR with the primer pairs shown in Table 1 . For all primer pairs, PCR was conducted for 40 cycles, each consisting of 2 mm at 95#{176}C, 2 miii at 55#{176}C, and 2 mm at 72#{176}C. Then 10% of the PCR products was electrophoresed in 1.5% agarose, transferred by the method of Southern onto a nylon membrane, and hybridized with a 32P-labeled full-length eDNA probe as described above.
A negative control, consisting of the entire PCR reaction mixture but without gDNA or eDNA, was included in every PCR experiment and was confirmed as negative as assessed by hybridization with the radiolabeled UROD eDNA probe.
Cloning and sequencing PCR products. Positively hybridizing PCR products were either extracted with phenol/chloroform (16) and precipitated or electrophoresed in low-melting-point agarose (USB Corp., Cleveland, OH). The appropriate band or bands were excised from the agarose gel, and the PCR products were extracted by Magic Prep (Promega) according to the manufacturer's instructions.
The amplified DNA was then sequenced directly or digested (with EcoRI and Hindill) and ligated into pUC13 (Promega) or blunt-ended and ligated into pBluescnpt (Stratagene, La Jolla, CA). At least six independent clones were characterized for indirect sequencing of PCR products. Direct and indirect sequencing of alternative transcripts was confirmed in both directions by using a modified version of the dideoxy method (19) with either Sequenase (USB Corp.) or T7 DNA polymerase (Pharmacia). Screening for UROD mRNA transcripts lacking exon 6. After synthesizing an i8-bp oligonucleotide probe that spanned the exon 5/exon 7 junction (JM5: GGTGC-CCCAGCATTGCAG), we end-labeled the oligonucleotide with y-32P-ATP (Bresatec), removing the free 32P-ATP with a NAP-5 column containing Sephadex G-25 medium (Pharmacia).
Products of the PCR amplification reactions were hybridized as described above, at 60#{176}C. The membrane was washed three times in 5x SSC containing 1 g/L SDS at room temperature for 15 mm, then once for 15 mm at 60#{176}C in 2 x SSC/i g/L SDS.
Results
Structure and Function of the UROD Gene and Its Product
Digestion of gDNA with BamHI and EcoRI followed by Southern analysis confirmed a normal configuration of the UROD gene in the normal individuals and in the fPCT patients with no evidence of deletions or rearrangements (Fig. 1) . This was supported by the data from Northern analysis and the assays of protein function. Analysis of poly(AY mRNA from leukocytes revealed only the predicted 1.2-kb UROD mRNA and precursor mRNA in normal subject #1 and the fPCT patients.
The failure of Northern analysis to demonstrate the presence of any smaller UROD mRNA transcripts suggested that they were not abundant (Fig. 2) . To study UROD function, we established a reference range for erythrocyte UROD activity from results for 20 healthy laboratory workers: 1.8-4.0 U/L. The erythrocyte UROD activity in the two normal individuals analyzed in this study was within the reference range 3.1 and 2.4 U/L, respectively, whereas that of the fPCT patients was -50% of normal (1.2 U/L for the proband and 1.3 U/L for her daughter). (Fig. 3) . The predicted size of the full-length PCR product was 1133 bp; however, the PCR products varied from 350 to 1133 bp and were observed both in the izormal individuals and in the patients with fPCT. Cloning and subsequent sequencing of these products revealed several alternative transcripts for UROD (Fig.  4) . All transcripts, including the full-length UROD transcript, were observed only after two rounds of PCR. The full-length UROD mRNA (transcript A) was observed in both IPCT patients and normal #1 but not in normal #2. This can be explained by the nature of PCR; namely, that small sequences of DNA are preferentially amplified over large ones. This phenomenon was probably enhanced in the study by our performing two rounds of PCR. Transcript B, which lacked exon 6, was identified by sequence analysis in the proband. Except for transcript G, which utilized a cryptic splice site in intron 1, all PCR products in which the nucleotide sequence was determined contained exons that abutted the previously defined exon boundaries.
Characterization of Intron/Exon Boundaries of UROD Gene
All intron/exon boundaries of the UROD gene were characterized and found to be identical in the two normal subjects and the proband. The splice donor and acceptor sequences complied with the known consensus sequences that flank intron/exon boundaries (5) and were identical to those previously published for the UROD gene with two exceptions: a single-base substitution in the exon 10 acceptor site and a single-base deletion in the exon 3 acceptor site. At the 3' end of intron 9 (the exon 10 acceptor site), a T-*C substitution was observed, TGTTGGTCCCCTAG/GAG to TGTTG-GTCCCCAG/GAG.
The deletion of an adenine at the 3' end of intron 2 (the acceptor site of exon 3) was also observed in all individuals:
CCTCATGTATGCAG/AGT to CCTCTGTATGCAG/AGT. These two changes were also observed in introns 2 and 9 of an independently derived UROD genomic clone that we have sequenced (data not shown). As discussed later, these changes are unlikely to be responsible for the multiple alternative transcripts we observed. In addition, characterization of the intron/exon junctions failed to identify any error at the genomic level to explain the mRNA lacking exon 6.
Single-Base Differences
Four additional deviations from the initial published sequence of the UROD gene have been described (7, 8) and all were observed in this study. They tccur at positions 87, 325, 931, and 1027 in the coding region and include a T-+C change at positions 87 (GCT-i.GC), 931 (TFG-TG), and 1027 (TFG-'TG)-none of which changes the encoded amino acids, alanine or leucine. However, at position 325, an A-'G substitution (AGC-GC) changes the amino acid deduced from the initial eDNA sequence from serine to glycine.
This glycine residue has been demonstrated by direct protein sequencing (5); it was also confirmed by our nucleotide sequence analysis, which showed this A-*G change in all individuals (6, 8) . A deviation not previously described was observed at positions 376, 377, and 378: GCG-*CGC.
All of these deviations from the initial published sequence were observed in all clones analyzed in this study.
Discussion
We describe here alternative splicing of mRNAs in the UROD gene that result in transcripts lacking between one and seven exons. Such splicing was observed both in normal individuals and two patients with fPCT.
Moreover, analysis of the UROD gene splice site sequences in the two normal subjects and the proband failed to explain these alternative transcripts.
Studies of the UROD gene have not greatly improved our understanding of the cause of fPCT at the molecular level. A single-point mutation in the coding region has been described at position 860 that results in the substitution of glycine for valine (7). In addition, an mRNA lacking exon 6 has been observed, attributed to a G-rC substitution at the junction of exon 6 and intron 6: CAGATGAGT to CAG/TGAGT. This abnormality was observed by Garey et al. (12) in about half of the PCR-generated clones analyzed after a single round of PCR amplification.
The same abnormality was found in 5 of 22 unrelated families with fPCT when an oligonucleotide probe containing the G-*C base substitution was used (12).
Several lines of evidence suggest that the alternative Although we observed two deviations from the published UROD gene splice sequences, Le., in the acceptor sites of exons 3 and 10, they are unlikely to have had any bearing on the alternative splicing events. The AG dinucleotide, which is conserved in >99% of intron/exon junctions studied (20) , was present at both sites. At the -3 position (the site of the T-i'C base alteration in intron 9), C occurs in 65% of splice junctions and T in 31%. At position -10, adenine is seen in only 15% of cases, and its deletion in intron 2 resulted in a thymine residue at this position, as observed in 49% of splice sites. From the results of these splice junction studies, the deviations observed in our subjects would probably have no effect on normal splicing. Precedent exists for alternative splicing of other genes. Alternative transcripts have been associated with point mutations in the splice site consensus sequences, especially those that flout the GT-AG rule (21-23) .
In the analysis of 139 splice junctions of nuclear and viral genes, a G occupied the first position of every intron (the donor site of every exon) (20) . However, several normally splicing genes possess splice sequences that fail to comply with the GT-AG rule. In most of these nonconsensus splice sites GT is replaced by GC. In such instances, the nucleotides that surround the CC dinucleotide in the splice junction show greater homology to the prototype consensus splice sequence and thus to Ui RNA than the average splice sequence (24), and probably allow normal splicing to proceed. In 
